Carisma Therapeutics Appoints Sanford Zweifach as Chairman to Board of Directors

November 29, 2021

PHILADELPHIA, November 29, 2021 – Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that Sanford (Sandy) Zweifach has been appointed to the chairman position for the Board of Directors. Mr. Zweifach joins Carisma as a senior executive with 30 years in the...

Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage

November 12, 2021

PHILADELPHIA, November 12, 2021, 12:10 PM ET-- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings from the landmark Phase 1 multi-center clinical trial of CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric...

CARISMA Announces Multiple Abstracts Accepted for Presentation at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

November 1, 2021

PHILADELPHIA, November 1, 2021 -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for...